Macromolecular Therapeutics Development

The Macromolecular Therapeutics Development Facility (MTDF) provides expertise for directed development and optimization of protein-based therapeutics and supports high-throughput automated development, analysis and production of protein reagents using a Bioemk FxP  liquid handling workstation for HTP molecular biology and expression testing, a Perkin-Elmer Cell::Explorer robot for very efficient HTP tissue culture based application and a custom microarray printer. This automation is designed to provide Einstein researchers with the added leverage of robotics equipment and trained personnel to accelerate and scale up their projects, thereby obviating the need for individual investigators to set up and staff their own facilities for protein production.


  • *Contact Ms. Susan Buhl for Monoclonal Antibodies
  • CLONING:
  • State of the art Robotics platforms for 96 well High Throughput
  • Vector Backbone Optimization (pET vector screen)
  • Purification Tag Optimization (including Linker Length)
  • 96 well high throughput mass mutagenesis. Potential uses include stability profiling and solubility enhancement.
  • EXPRESSION:
  • E.Coli
  • Shake Flask (48 Liter Capacity)
  • Single Cell (2 L) Fermentation
  • High Throughout 96 well (65ml) Fermentation
  • Baculovirus (SF9, S2)
  • Shake Flasks (10 L Capacity)
  • Mammalian (HEK293T)
  • Roller Bottle (48 1/2 liter capacity)
  • PURIFICATION:
  • Column Purification, all types (Affinity, Size Exclusion, etc)
  • AKTA Express systems for hands off automated purification of 8
  • AKTA Purifier for single step purifications
  • MONOCLONAL ANTIBODY GENERATION AND PRODUCTION:
  • Generation of hybridomas making mouse or rat monoclonal antibodies
  • Immunization of animals
  • Fusions to generate hybridomas
  • Assay of antibody responses and identification of mice for fusions
  • Screening of fusions for positive hybridomas
  • Subcloning of positive hybridomas
  • Freezing of useful hybridomas
  • Maintain a backup of frozen stocks
  • Generation of class switch variants of existing monoclonal antibodies
  • Production of high concentrations of monoclonal antibodies
  • CONSULTATION ON:
  • Cloning,expression and purification of protein
  • Strategies to obtain useful monoclonal antibodies
  • Letters in support of grant applications

Related Shared Facilities
Related Shared Facilities

Structural NMR

X-Ray Crystallography

Center Affiliations
Center Affiliations

Montefiore Einstein Cancer Center

Location and Contacts

Macromolecular Therapeutics Development Price Center/Block Research Pavillion 313
  • Steven C. Almo, Ph.D.
    Scientific Director
    718-430-2746

  • Scott Garforth, Ph.D.
    Operations Director
    718.678.1146

  • Matthew D. Scharff, M.D.
    Co-Scientific Director (Monoclonal Antibodies)
    718-430-3527

  • Susan Buhl
    Associate Director (Monoclonal Antibodies)
    718-430-2170